mafosfamide has been researched along with mitomycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, MR; Friedl, P; Rozycki-Gerlach, W; Schlag, P; Schmähl, D; Yi, J | 1 |
| Fabian, K; Kaina, B; Thacker, J; Tsaryk, R | 1 |
2 other study(ies) available for mafosfamide and mitomycin
| Article | Year |
|---|---|
First experiments with locoregional chemotherapy in the treatment of autochthonous rat hepatoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diethylnitrosamine; Female; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms, Experimental; Mitomycin; Mitomycins; Rats; Rats, Inbred Strains; Sarcosine; Thiocarbamates; Triazoles | 1988 |
Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cisplatin; Cyclophosphamide; Dacarbazine; DNA-Binding Proteins; Humans; Methylnitronitrosoguanidine; Mitomycin; Mutagens; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2006 |